Skip to search boxSkip to navigationSkip to main content

Poor prognosis acute myelogenous leukemia 2 - Biological and molecular biological characteristics and treatment outcome

  • Biaoru Li
    ,
  • Jie Yang
    ,
  • Ming Tao
    ,
  • Jaya Nayini
    ,
  • Erzsebet Horvath
    ,
  • Harpareet Chopra
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Biological and molecular biological studies were performed on the marrow cells of 25 patients with poor prognosis AML to both characterize this type of leukemia and to assess the relationship between the parameters which were measured and treatment outcome. Treatment failure associated with high levels of telomerase activity and low levels of IL6 transcripts. Studies of the effects of amifostine on these parameters demonstrated that this agent reduced telomerase activity in aspirates of AML marrows. These data suggest that the beneficial effect associated with the administration of amifostine after the end of chemotherapy is likely, to be due to a reduction in the rate at which the surviving leukemia cells repopulate the marrow. Copyright (C) 2000 Elsevier Science Ltd.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 777-789 (13 pages)

Journal (Volume, Issue Number)

Leukemia Research (Volume 24, Issue 9)

Publication milestones

  • Published - 09/01/2000

Publication status

Published - 09/01/2000

ISSN

0145-2126

Publication IDs

  • Scopus: 0034284015
  • PubMed: 10978783

Publication metrics

Metrics

SciVal
FWCI
0.22
SciVal
Author count
9
SciVal
citations
3
SciVal
Paper percentile
39
Scopus
citations
Fractional count
1
Fractional count
0.11
Fractional count
8
Fractional count
0.89
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
6
Citation count
5

Funding Details

This work is supported by, the National Institute of Health/National Cancer Institute PO-1 CA75606-3 and by a contribution from the AIza Corporation. B. Li provided analysis and data interpretation, drafted the article and gave critical revision. J. Yang and J. Navini assisted with data interpretation. E. Horvath collected the data and provided technical support. H. Chopra provided data interpretation. P.M. Meyer provided statistically expertise. P. Venugopal provided study material, gave critical support to the review and gave final approval. H.D. Preisler provided the concept, design, assisted with data interpretation and drafting the article, obtained funding, gave administrative support and gave final approval.